Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Paul M. Barr et al.|New England Journal of Medicine|2014Cited by 1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer A. Woyach, Jennifer R. Brown et al.|American Journal of Hematology|2019Cited by 472
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313
Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational studyRosa Ruchlemer, Tamar Lachish, Ronen Ben‐Ami et al.|Mycoses|2019Cited by 80
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPaul M. Barr, Susan O’Brien, Alessandra Tedeschi et al.|Blood|2019Cited by 2